|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Complement C3 purified from human plasma.|
|Storage buffer||HEPES with 0.15M NaCl, 0.01% BSA, 50% glycerol|
|Contains||0.03% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay dependent|
|Western Blot (WB)||2 ug/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 1 publications below|
A suggested positive control for this product is human plasma.
Human Complement C3 (C3) is synthesized as a single-chain pro-molecule (185kDa) that then suffers several post-translational modifications. Before being secreted as a mature protein, C3 is split into b-chain (645 residues and 70kDa) and a-chain (992 residues and 115 kDa) and forms a rare internal thioester bond. C3 plays a central role in the activation of all the three pathways of complement activation i.e. the classical, alternative, and lectin pathway. As C3 is the major complement component and participates in several stages of the immune response, its deficiency generally associated with higher susceptibility to severe bacterial infections and in some cases with autoimmune diseases such as systemic lupus erythematosus.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Commercially available complement component-depleted sera are unexpectedly codepleted of ficolin-2.
LF-MA0132 was used in flow cytometry to study the presence or absence of ficolins in commercial complement component-depleted sera
|Brady AM,Geno KA,Dalecki AG,Cheng X,Nahm MH||Clinical and vaccine immunology : CVI (21:1323)||2014|